CL2019000270A1 - Composición de cannabis. - Google Patents

Composición de cannabis.

Info

Publication number
CL2019000270A1
CL2019000270A1 CL2019000270A CL2019000270A CL2019000270A1 CL 2019000270 A1 CL2019000270 A1 CL 2019000270A1 CL 2019000270 A CL2019000270 A CL 2019000270A CL 2019000270 A CL2019000270 A CL 2019000270A CL 2019000270 A1 CL2019000270 A1 CL 2019000270A1
Authority
CL
Chile
Prior art keywords
extremely
cannabis
fraction
invention refers
terpene
Prior art date
Application number
CL2019000270A
Other languages
English (en)
Inventor
Harry Karelis
Mara Gordon
Stewart Smith
Stewart Washer
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61072172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019000270(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of CL2019000270A1 publication Critical patent/CL2019000270A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN MÉTODO PARA TRATAR UN TRASTORNO DEL SUEÑO. PREFERENTEMENTE, LA INVENCIÓN SE REFIERE A UN MÉTODO PARA TRATAR UN TRASTORNO DEL SUEÑO QUE COMPRENDE LA ETAPA DE ADMINISTRAR UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN EXTRACTO DE CANNABIS Y OPCIONALMENTE UNO O MÁS PORTADORES, DILUYENTES, ADYUVANTES, EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES O CUALQUIER COMBINACIÓN DE ESTOS, EL EXTRACTO DE CANNABIS QUE COMPRENDE UNA FRACCIÓN DE TERPENO QUE COMPRENDE LIMONENO EN UNA CANTIDAD DE AL MENOS APROXIMADAMENTE 5.4 % EN PESO DE LA FRACCIÓN DE TERPENO.
CL2019000270A 2016-08-03 2019-01-31 Composición de cannabis. CL2019000270A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662370304P 2016-08-03 2016-08-03

Publications (1)

Publication Number Publication Date
CL2019000270A1 true CL2019000270A1 (es) 2019-10-04

Family

ID=61072172

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000270A CL2019000270A1 (es) 2016-08-03 2019-01-31 Composición de cannabis.

Country Status (15)

Country Link
US (2) US11779562B2 (es)
EP (1) EP3493798A4 (es)
JP (1) JP2019523283A (es)
KR (2) KR20190035791A (es)
CN (1) CN109843287A (es)
AU (4) AU2017307643B2 (es)
BR (1) BR112019001852A2 (es)
CA (1) CA3031810A1 (es)
CL (1) CL2019000270A1 (es)
CO (1) CO2019001044A2 (es)
IL (2) IL296008B1 (es)
MX (1) MX2019001285A (es)
PE (1) PE20200726A1 (es)
SG (1) SG11201900665VA (es)
WO (1) WO2018023163A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019001286A (es) 2016-08-03 2019-06-13 Zelda Therapeutics Operations Pty Ltd Composicion de cannabis.
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
BR112019020554A2 (pt) * 2017-03-30 2020-04-28 Ojai Energetics Pbc métodos e composições para melhorar as condições de saúde
MX2019015315A (es) * 2017-06-19 2020-02-17 Zelda Therapeutics Operations Pty Ltd Composiciones y tratamientos para el trastorno del sueño.
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
WO2019173242A1 (en) * 2018-03-04 2019-09-12 Cmg Partners, Inc. Enhanced smokable cannabis-based therapeutic product for treatment of sleep disorders and chronic pain and method for making same
US20210251949A1 (en) * 2018-06-15 2021-08-19 California Cannabinoids Compositions and Methods for Treatment of Narcolepsy and Related Disorders
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
US20220160648A1 (en) * 2019-02-13 2022-05-26 Inspired Health Products, LLC Composition Comprising Hydrolyzed Collagen and Cannabidiol and Use Thereof
US11554098B2 (en) 2019-05-03 2023-01-17 HFL Partners, LLC Compositions comprising molecularly separated cannabinoids and terpene blends and methods of producing
US20230000935A1 (en) * 2021-07-03 2023-01-05 Joseph Anthony Bidwell Extract Infused Cannabis Flower, Natural preservation of Cannabis Flower and the method therefor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2400319B (en) 2001-05-04 2005-06-08 Gw Pharma Ltd Cannabinoid-rich extracts
JP4411117B2 (ja) * 2004-03-25 2010-02-10 エスエス製薬株式会社 睡眠改善医薬組成物
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
JP2007246428A (ja) * 2006-03-15 2007-09-27 Nature Technology Inc 植物精油成分を有効成分とする経皮吸収型睡眠覚醒用医薬組成物、その組成物を含有する経皮吸収型睡眠覚醒用医薬製剤、及びこれらの製造方法
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
KR20110120153A (ko) * 2010-04-28 2011-11-03 고려대학교 산학협력단 리모넨을 함유하는 아데노신 Ａ2ａ 수용체 작용제
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
DK2844243T3 (da) 2012-05-03 2020-02-03 Echo Pharmaceuticals Bv Fremgangsmåde til fremstilling af et cannabisplante-isolat omfattende delta-9-tetrahydrocannabinol
US20150313868A1 (en) * 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
CA2904968A1 (en) 2013-03-14 2014-10-02 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
US9095554B2 (en) * 2013-03-15 2015-08-04 Biotech Institute LLC Breeding, production, processing and use of specialty cannabis
US10265292B2 (en) 2013-09-18 2019-04-23 The Werc Shop, LLC Terpene-based compositions, processes methodologies
PL3062606T3 (pl) * 2013-10-29 2019-09-30 Biotech Institute, Llc Hodowla, produkcja, przeróbka oraz zastosowanie specjalnych konopi
CN105916492A (zh) 2013-10-31 2016-08-31 全谱实验室有限公司 萜烯和大麻素制剂
CA2952934A1 (en) * 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
ES2877361T3 (es) 2014-06-27 2021-11-16 Farm To Farma Inc Formulaciones de cannabinoides bucales y sublinguales y método para hacer las mismas
AU2015308546A1 (en) * 2014-08-25 2017-04-13 Clk Consult V/ Carsten Leonhard Knudsen Device with compositions for delivery to the lungs, the oral mucosa and the brain
BR122021018502B1 (pt) 2014-10-21 2022-05-03 United Cannabis Corp Formulação de canabinoide líquida
JP2018505912A (ja) 2014-12-12 2018-03-01 オーハイ エナジェティクス ピービーシー マイクロカプセル化カンナビノイド組成物
US10406186B2 (en) 2015-01-31 2019-09-10 Constance Therapeutics, Inc. Cannabis oil extracts and compositions
WO2016138505A1 (en) 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
WO2018023164A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
MX2019001286A (es) 2016-08-03 2019-06-13 Zelda Therapeutics Operations Pty Ltd Composicion de cannabis.

Also Published As

Publication number Publication date
WO2018023163A1 (en) 2018-02-08
AU2019253841B2 (en) 2021-07-01
IL296008B1 (en) 2024-05-01
AU2018100923B4 (en) 2018-09-27
AU2021240297B2 (en) 2023-08-24
MX2019001285A (es) 2019-06-13
JP2019523283A (ja) 2019-08-22
PE20200726A1 (es) 2020-07-21
EP3493798A4 (en) 2020-05-06
US11779562B2 (en) 2023-10-10
BR112019001852A2 (pt) 2019-05-07
KR20190035791A (ko) 2019-04-03
AU2017307643B2 (en) 2019-07-25
CA3031810A1 (en) 2018-02-08
US20230414559A1 (en) 2023-12-28
AU2019253841A1 (en) 2019-11-14
IL264461A (en) 2019-02-28
IL264461B1 (en) 2024-05-01
CO2019001044A2 (es) 2019-04-30
AU2021240297A1 (en) 2021-10-28
EP3493798A1 (en) 2019-06-12
IL296008A (en) 2022-10-01
AU2018100923C4 (en) 2019-10-31
AU2017307643A1 (en) 2018-07-05
US20220347155A1 (en) 2022-11-03
SG11201900665VA (en) 2019-02-27
KR20210013645A (ko) 2021-02-04
CN109843287A (zh) 2019-06-04
AU2018100923A4 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
CL2019000270A1 (es) Composición de cannabis.
CL2019000266A1 (es) Composición de cannabis.
CL2019000268A1 (es) Composición de cannabis.
CO2017008437A2 (es) Métodos de purificación de cannabinoides, composiciones y kits de los mismos
CL2019003635A1 (es) Composiciones y tratamientos para el trastorno del sueño.
UY37581A (es) Compuestos para el tratamiento de la infección por virus de la hepatitis b
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CR20190403A (es) Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
PE20171138A1 (es) Modulacion inmunitaria
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
AR101740A1 (es) Terapia de combinación y composiciones
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
DOP2017000049A (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
GT201700124A (es) Formulación de relación fija de insulina glargina/lixisenatida
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe